PM
BTAI icon

Prosight Management’s BioXcel Therapeutics BTAI Stock Holding History

Prosight Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,863
Closed -$1.29M – 44
2020
Q3 		$1.29M Buy
+1,863
New +$1.4M 0.61% 37

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Prosight Management's BTAI Position: Q4 2020 in Review

Prosight Management sold out of BioXcel Therapeutics (BTAI) in Q4 2020, closing a stake of 1,863 shares — an estimated $1.29M sold.

Prosight Management first reported a position in BTAI in Q3 2020 and held it in 1 quarter. The position peaked at $1.29M in Q3 2020. 117 funds tracked by Wall St. Rank hold BTAI as of Q4 2020.

  • Prosight Management reported no remaining BioXcel Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Prosight Management sold 1,863 BioXcel Therapeutics shares in Q4 2020, an estimated $1.29M.
  • Prosight Management first reported a position in BioXcel Therapeutics in Q3 2020 and held it in 1 quarter.
  • Prosight Management's BioXcel Therapeutics position peaked at $1.29M in Q3 2020.
  • 117 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2020.

Based on Prosight Management's 13F filing for Q4 2020, filed 12 Feb 2021.